Event Title

P-24 Effectiveness of Novel Heterocyclic Aurone Drugs in the Treatment of Glioblastoma

Presenter Information

Jangwon Seo

Start Date

2-28-2020 2:30 PM

Description

This research project involved synthesis of novel aurone heterocycle, and then testing their anticancer properties on glioblastoma cell lines. Glioblastoma is a deadly form of brain cancer, and upon diagnosis, the average survival time is only 15 months, with current treatment only extending it for a few additional months. Aurones are a subset of flavonoids, which are secondary plant metabolites known to have anticancer properties. This project was interested in seeing if different hybrids of these compounds would have an additive or synergistic anti-cancerous effect on the glioblastoma cells.

Acknowledgments

J.N. Andrews Honors Scholar

Mentor: Denise Smith, Biology

This document is currently not available here.

Share

COinS
 
Feb 28th, 2:30 PM

P-24 Effectiveness of Novel Heterocyclic Aurone Drugs in the Treatment of Glioblastoma

This research project involved synthesis of novel aurone heterocycle, and then testing their anticancer properties on glioblastoma cell lines. Glioblastoma is a deadly form of brain cancer, and upon diagnosis, the average survival time is only 15 months, with current treatment only extending it for a few additional months. Aurones are a subset of flavonoids, which are secondary plant metabolites known to have anticancer properties. This project was interested in seeing if different hybrids of these compounds would have an additive or synergistic anti-cancerous effect on the glioblastoma cells.